This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Merck & Co., Inc.
Drug Names(s): CDB-1, MBL-CDB1, MDX-1388, MK-6072, Zinplava
MK-6072 is a fully human antibody developed to target and neutralize the effects of Toxin B, a toxin produced by the bacterium C. difficile.
MK-6072 is also being developed in a fixed dose combination with MK-3415, seen here.
Deal Structure: CDA-1 and CDB-1 were co-developed by Medarex and Massachusetts Biologic Laboratories (MBL).
In April 2009, Merck & Co, Medarex, and MBL of the University of Massachusetts Medical School (UMMS) announced that they signed an exclusive worldwide license agreement for CDA-1 and CDB-1 (also known as MDX-066/MDX-1388 and MBL-CDA1/MBL-CDB1). Under the terms of the agreement, Merck gains worldwide rights to develop and commercialize CDA-1 and CDB-1. Medarex and MBL will receive an upfront payment of $60 million and are potentially eligible to receive additional cash payments up to $165 million upon achievement of certain milestones associated with the development and approval of a drug candidate covered by this agreement. Upon commercialization, Medarex and MBL will also be eligible to receive double-digit royalties on product sales and milestones if certain sales targets are met. In accordance with the co-development agreement between Medarex and MBL, all payments will be divided...See full deal structure in Biomedtracker
Partners: Bristol-Myers Squibb Company
Additional information available to subscribers only: